Shield Therapeutics Announces Acceptance of ST10 Abstract for Presentation at ECCO Congress 2014 in Copenhagen

4 Feb 2014

Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO, taking place from February 20 – 22 in Copenhagen, Denmark.

As recently announced, ST10, a novel orally-dosed form of ferric iron, successfully met both the primary and secondary endpoints of the AEGIS pivotal Phase III programme. With a mean increase of 2.3g/dL in ST10-treated subjects, the results of the study strongly demonstrated ST10’s potential to be the only effective oral treatment for ferrous intolerant IDA patients, in addition to being an effective alternative to intravenous iron treatment.

The abstract about ST10, entitled “Correcting iron deficiency anaemia in IBD: A pivotal phase 3 study of a novel oral ferric iron”, will be presented during the Digital Oral Poster Session 9 – Therapy today – in Room 9, Hall B on the Ground level of the Bella Centre at 13.07 on Friday 21st February 2014.

Back to news